Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial

BACKGROUND: Tumour necrosis factor inhibitors (TNFi) are effective in the treatment of patients with spondyloarthritis (SpA), including psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). However, these drugs come with some disadvantages such as adverse events, practical burden for patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Michielsens, Celia A. J., Boers, Nadine, den Broeder, Nathan, Wenink, Mark H., van der Maas, Aatke, Mahler, Elien A. M., Mulder, Michelle L. M., van der Heijde, Désirée, van den Hoogen, Frank H. J., Verhoef, Lise M., den Broeder, Alfons A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964104/
https://www.ncbi.nlm.nih.gov/pubmed/31941544
http://dx.doi.org/10.1186/s13063-019-4000-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964104/
https://www.ncbi.nlm.nih.gov/pubmed/31941544
http://dx.doi.org/10.1186/s13063-019-4000-5

Ejemplares similares